All Trials

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic CLDN18.2-positive gastric/GEJ, pancreatic ductal, or biliary tract adenocarcinomas receive spevatamig (PT886)—a bispecific antibody targeting CLDN18.2 and CD47 to enhance macrophage-mediated phagocytosis—given as monotherapy or combined with chemotherapy (e.g., paclitaxel, gemcitabine/nab-paclitaxel, FOLFOX, CAPOX, FOLFIRINOX) and/or pembrolizumab. Cohorts are line- and disease-specific, with CLDN18.2 expression ≥10% at ≥2+ required for combination parts.

ClinicalTrials.gov ID: NCT05482893

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma after prior systemic therapy receive AZD5863 monotherapy, a CLDN18.2×CD3 T cell–engaging bispecific antibody, via IV or SC administration. Trial focuses on dose finding and preliminary efficacy with RECIST-measurable disease and ECOG 0–1 required.

ClinicalTrials.gov ID: NCT06005493

A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory/relapsed pancreatic ductal adenocarcinoma (ECOG 0–1) receive a single infusion of autologous B7-H3 (CD276)–targeted CAR-T cells incorporating an inducible caspase-9 safety switch. Dose-escalation evaluates safety/tolerability and feasibility; bridging therapy may be used pre-infusion.

ClinicalTrials.gov ID: NCT06158139

A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated metastatic pancreatic adenocarcinoma (including adenosquamous) with liver metastasis, ECOG 0–1, and no brain mets receive modified gemcitabine/cisplatin/nab-paclitaxel every 2 weeks plus continuous Tumor Treating Fields (TTF), followed by maintenance gemcitabine with TTF. TTF is a noninvasive device therapy delivering alternating electric fields that disrupt mitosis; key exclusions include significant cardiac conduction issues/implantable stimulators and inability to use the device.

ClinicalTrials.gov ID: NCT04605913

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced/metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive the anti-PAUF monoclonal antibody PBP1510 (ulenistamab)—a first-in-class IgG1 that neutralizes PAUF-mediated ERK/JNK/AKT and TLR2/4 signaling—given as monotherapy in dose escalation and then combined with gemcitabine at RP2D. Prior gemcitabine is allowed (unless stopped for intolerance), and the expansion focuses on PBP1510 plus gemcitabine to assess safety and antitumor activity.

ClinicalTrials.gov ID: NCT05141149

Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Untreated metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receiving mFOLFIRINOX plus oral zunsemetinib, an investigational inhibitor of the p38α–MK2 signaling axis intended to reduce proinflammatory cytokine expression and potentially chemosensitize tumors. Key exclusions include CNS metastases, ≥grade 2 neuropathy, significant ILD, QTcF >460 ms, strong CYP3A4/2C8 modulators, and QT‑prolonging drugs.

ClinicalTrials.gov ID: NCT06648434

Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with stage III locally advanced pancreatic adenocarcinoma receive irreversible electroporation of the primary tumor with peri-ablation systemic chemotherapy continued from their pre-IRE regimen (FOLFIRINOX or gemcitabine). The study assesses safety and progression outcomes of adding IRE to standard chemotherapy in this non-randomized single-arm setting.

ClinicalTrials.gov ID: NCT03484299

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic PDAC, gastric/GEJ, or biliary tract cancers (ECOG 0–1) after at least one prior systemic therapy receive AZD4360 monotherapy. AZD4360 is an investigational CLDN18.2-targeted agent (modality not disclosed) in first-in-human dose escalation/expansion to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06921928

Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced, unresectable, nonmetastatic pancreatic adenocarcinoma (ECOG 0–1), including those after induction chemotherapy, receive concurrent weekly gemcitabine plus nab-paclitaxel (microtubule inhibitor; radiosensitizer) with hypofractionated ablative proton therapy (67.5 Gy/15 fx), followed by surgical exploration if feasible. Excludes prior overlapping abdominal RT or significant neuropathy; evaluates dose tolerance, safety, response, and resection potential.

ClinicalTrials.gov ID: NCT03652428

Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable HCC not eligible for curative therapy (Child-Pugh A/B7, ECOG 0–2) and at least one TACE-amenable lesion receive TACE (up to 3 sessions) plus a single priming dose of nivolumab/ipilimumab followed by maintenance nivolumab and cabozantinib 40 mg daily. Cabozantinib is a multi–tyrosine kinase inhibitor (MET/VEGFR2/AXL) combined here with PD‑1 and CTLA‑4 blockade to enhance locoregional and systemic antitumor activity.

ClinicalTrials.gov ID: NCT04472767